#104: Revolutionizing Respiratory Antivirals: The Science behind G.ST Antivirals

On this episode of "Year in Review Recording," we speak with Guido Gualdoni, Co-Founder, and CEO of G.ST Antivirals, a clinical-stage biotech company revolutionizing how we treat viral infections of the respiratory tract. 

Guido shares the science behind G.ST Antivirals' innovative host cell-based strategy to develop broad-spectrum antivirals and how it completely eliminates viral reproduction without the risk of resistance development. He also delves into the public funding and startup ecosystem in Vienna, Austria, which has been instrumental in the company's success. 

He also talks about the future plans for G.ST Antivirals and the deep scientific tech valley in Central Europe. This episode is a must-listen for anyone interested in the latest advancements in biotech and the companies leading the way in treating viral infections.

 💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2
Watch on Youtube
Guido Gualdoni
Christian Soschner

⏰  Timestamps:
(00:00) Welcome to the Episode: Exploring the Public Funding and Eco-System in Vienna, Austria
(02:35) Meet Guido Gualdoni, CEO of G.ST Antiviral
(04:00) Discovering the StartUp Labs, Vienna Business Agency, AWS, FFG, Austrian Business Agency, LISA Vienna and their role in supporting startups
(07:35) Exploring the Scientific Deep Tech Valley in Central Europe: Munich, Vienna, Zurich, Prague
(10:15) G.ST Antiviral's 2022 Outlook
(11:22) Uncovering the Innovative Technology Behind G.ST Antiviral
(14:30) Guido's Biggest Takeaways from 2022
(16:15) Why Optimism Bias Can be a Challenge for Entrepreneurs
(18:15) Comparing the Scientific and Entrepreneurial Mindsets
(24:00) The Surprising Companies that Succeeded During Economic Downturns
(25:00) Examining the Latest Trends in Antiinfectious Diseases
(27:45) Charting the Growth of G.ST Antiviral in 2023

Send us a text

Support the show

Join the Podcast Newsletter: Link